TABLE 1.
Characteristics Evaluated | All Youth Aged 10 to 17 y (n = 4263, Estimated 33.2 million in United States), % | Youth With HA (10.6%; n = 434; Estimated 3.52 million), % | Youth With HA who DID NOT Use CAM (70.4%; n = 296; Estimated 2.46 million), % | Youth with HA Who Used CAM (29.6%, n = 133; Estimated 1.03 million), % |
---|---|---|---|---|
Agea | ||||
10–12 y (n = 1437) | 36.7 | 31.4 | 35.4 | 22.0 |
13–15 y (n = 1591) | 36.7 | 33.9 | 32.6 | 36.7 |
16–17 y (n = 1235) | 26.5 | 34.7 | 32.1 | 41.3 |
Gender | ||||
Male (n = 2248) | 51.3 | 46.5 | 48.9 | 40.7 |
Female (n = 2015) | 48.7 | 53.5 | 51.1 | 59.3 |
Race/ethnicitya | ||||
Hispanic (n = 1160) | 19.0 | 21.0 | 23.6 | 14.4 |
White, non-Hispanic (n = 2028) | 59.1 | 59.5 | 54.4 | 73.4 |
African American, non-Hispanic (n = 743) | 15.1 | 13.6 | 16.0 | 6.8 |
Asian, non-Hispanic (n = 208) | 3.6 | 1.3b | 1.2b | 1.7b |
Multi/Other, non-Hispanic (n = 124) | 3.3 | 4.5 | 4.9 | 3.7 |
Family incomea | ||||
0% to 99% FPL (n = 676) | 15.3 | 21.4 | 25.1 | 11.9 |
100% to 199% FPL (n = 990) | 23.7 | 26.0 | 27.3 | 23.6 |
200% to 399% FPL (n = 1325) | 31.7 | 30.8 | 27.9 | 37.9 |
400% FPL or above (n = 1272) | 29.4 | 21.9 | 19.7 | 26.7 |
Maternal educationa | ||||
Less than high school (n = 692) | 14.8 | 15.5 | 17.9 | 10.1 |
High school or GED (n = 1031) | 26.9 | 23.9 | 26.3 | 18.0 |
More than high school (n = 2103) | 58.3 | 60.6 | 55.8 | 71.9 |
Insurance typea | ||||
Public insurance only (n = 1065) | 24.2 | 28.2 | 29.4 | 24.8 |
Any private insurance (n = 2664) | 65.0 | 59.1 | 55.0 | 69.5 |
Uninsured (n = 513) | 10.9 | 12.7 | 15.6 | 5.7b |
Co-occurring chronic conditions | ||||
Has at least 1+ chronic conditions or problems assessed in NHISc (other than HA) (n = 2383) | 56.6 | 86.4 | 83.3 | 94.0g |
Has 1+ emotional, mental or behavioral health condition or problemd (n = 858) | 20.7 | 44.8 | 42.5 | 51.0 |
Has 1+ non-HA pain related conditionse (n = 517) | 12.1 | 38.1 | 32.7 | 50.9g |
Other limitations and difficulties | ||||
Missed 2+ weeks of school/year (n = 202) | 4.7 | 12.0 | 7.7 | 22.1g |
Limited in daily activities due to healthf (n = 380) | 9.4 | 17.8 | 14.5 | 25.4g |
Definite/severe difficulties in emotions, concentration or behavior (n = 224) | 6.2 | 14.6 | 12.6 | 19.5g |
χ2 test: differences between youth with HA who used CAM and who did not use CAM are statistically significant at a .05 level of significance.
Cells do not meet standards of precision (relative SE >30%).
Chronic conditions: arthritis, other chronic pain, anxiety/stress, depression, attention-deficit disorder/attention-deficit/hyperactivity disorder, phobia/fears, insomnia/trouble sleeping, bedwetting/incontinence, food/digestive allergies, frequent diarrhea/colitis, acid reflux/heartburn, recurring constipation, asthma, hay fever, respiratory allergies, other lung/breathing problem, other allergies, 3 or more ear infections, autism, cerebral palsy (only last 2 quarters of data due to data validity issue noted by the National Center for Health Statistics),62 Down syndrome, muscular dystrophy, mental retardation, speech problems, developmental delay, learning disability, seizure, other neurologic problems, hearing problems, vision problems, eczema/skin allergy, severe acne, cancer, congenital heart disease, cystic fibrosis, diabetes, other heart problems, problems with being overweight, menstrual problems, fatigue/lack of energy, gum disease, anemia, and sickle cell anemia.
EMB conditions/problems: anxiety/stress, depression, attention-deficit disorder/attention-deficit/hyperactivity disorder, phobia/fears, insomnia/trouble sleeping, and incontinence/bedwetting.
Non-HA pain-related conditions/problems: arthritis, abdominal pain, back/neck pain, and other chronic pain.
Limited in personal care, difficulty walking without using any special equipment, difficulty remembering or experience periods of confusion, receive Special Education or Early Intervention Services or limited in any way not previously mentioned.
t test: differences between youth with HA who used CAM and who did not use CAM are statistically significant at a .05 level of significance.